nevirapine

Switch to nevirapine at any count

Graham Stocks — Wed, 01 Dec 2010 16:47:51 -0800

People with HIV who have an undetectable viral loadA measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma. can safely switch to nevirapine (Viramune) at any CD4 cell count, the European Medicines Agency has concluded.

News from IAS 2010

Graham Stocks — Wed, 01 Sep 2010 22:09:07 -0700

Adrian Ogier gives a round up of treatments news from the Vienna Conference.

Treatments news from the IAS Conference

Wed, 19 Aug 2009 18:52:42 -0700

A roundup of HIV treatments developments from the IAS Conference in Cape Town.

Non-nukes

Paul Kidd — Sun, 09 Jul 2006 07:07:15 -0700

Non-nucleosides are a powerful option for treating HIV, but cross-resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. can mean you only get one bite of the cherry. This is the final instalment in a three-part series looking at key drug classesA group of anti-HIV drugs with the same target of action. Anti-HIV drug classes include nucleoside analogue reverse transcriptase inhibitors, protease inhibitors and non-nucleoside analogue reverse transcriptase inhibitors, as well as several others. Combining drugs from three or more classes is the basis of Highly Active Antiretroviral Therapy (HAART)..

News and treatments briefs

Paul Kidd — Sat, 14 Feb 2004 12:00:10 -0800

HIV-related news in brief from the Feb-Mar 2004 edition of Positive Living.

The power of one

Paul Kidd — Sun, 14 Dec 2003 12:00:21 -0800

We all want simpler treatment regimens with fewer side effects and no meal restrictions, right? Well how does once-a-day treatment sound? As PAUL KIDD reports, it may be closer than you think.

News and treatments briefs

Paul Kidd — Sat, 31 May 2003 07:00:48 -0700

HIV-related news in brief from the June-July 2003 edition of Positive Living.

Retro roundup

Paul Kidd — Mon, 31 Mar 2003 14:00:13 -0800

The 10th Conference on Retroviruses and Opportunistic Infections took place in Boston in February. This annual conference is a very highly regarded event with a strong scientific focus, so it often produces a number of important advances in our understanding of HIV and its treatment, and this year was no exception.